Detail akcie Insmed online

Business Summary: Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Insmed Inc revenues increased 32% to $342.6M. Net loss increased 40% to $948.3M. Revenues reflect US segment increase from $66.9M to $235M, Europe and rest of worldld segment increase from $5.6M to $54.8M. Higher net loss reflects General and Administrative - other increase of 53% to $255.3M (expense), Other Non Operating I/E increase of 71% to $182M (expense).